Pasar al contenido principal

DESARROLLO DE PEPTIDOS NEUROPROTECTORES MEDIANTE EL ANALISIS INTEGRAL DE LA INACTIVACION DE LAS VIAS DE SUPERVIVENCIA DEL NMDAR Y TRKB EN ISQUEMIA

BFU2013-43808-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación

Integral characterization of defective BDNF/TrkB signalling in neurological and psychiatric disorders leads the way to new therapies

  • Tejeda, Gonzalo S.
  • Díaz-Guerra, Margarita
This article belongs to the Special Issue Brain-Derived Neurotrophic Factor., Enhancement of brain-derived neurotrophic factor (BDNF) signalling has great potential in therapy for neurological and psychiatric disorders. This neurotrophin not only attenuates cell death but also promotes neuronal plasticity and function. However, an important challenge to this approach is the persistence of aberrant neurotrophic signalling due to a defective function of the BDNF high-affinity receptor, tropomyosin-related kinase B (TrkB), or downstream effectors. Such changes have been already described in several disorders, but their importance as pathological mechanisms has been frequently underestimated. This review highlights the relevance of an integrative characterization of aberrant BDNF/TrkB pathways for the rational design of therapies that by combining BDNF and TrkB targets could efficiently promote neurotrophic signalling., We acknowledge funding from Ministerio de Economía y Competitividad (BFU2013-43808-R) and Fundación Mutua Madrileña (reference No. 201322001). The cost of this publication has been paid in part by FEDER funds., We acknowledge support by the CSIC Open Access Publication Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain ischaemia induces shedding of a BDNF-scavenger ectodomain from TrkB receptors by excitotoxicity activation of metalloproteinases and γ-secretases

  • Tejeda, Gonzalo S.
  • Ayuso Dolado, Sara
  • Arbeteta, Raquel
  • Esteban-Ortega, Gema M.
  • Gómez Vidaurre, Óscar
  • Díaz-Guerra, Margarita
Stroke remains a leading cause of death and disability in the world with limited therapies available to restrict brain damage or improve functional recovery after cerebral ischaemia. A promising strategy currently under investigation is the promotion of brain-derived neurotrophic factor (BDNF)-signalling through tropomyosin-related kinase B (TrkB) receptors; a pathway essential for neuronal survival and function. However, TrkB and BDNF-signalling are impaired by excitotoxicity, a primary pathological process in stroke also associated with neurodegenerative diseases. Pathological imbalance of TrkB isoforms is critical in neurodegeneration and is caused by calpain-processing of BDNF high affinity full-length receptor (TrkB-FL) and an inversion of the transcriptional pattern of the Ntrk2 gene, to favour expression of the truncated isoform TrkB-T1 over TrkB-FL. We report here that both TrkB-FL and neuronal TrkB-T1 also undergo ectodomain shedding by metalloproteinases activated after ischemic injury or excitotoxic damage of cortical neurons. Subsequently, the remaining membrane-bound C-terminal fragments (CTFs) are cleaved by ¿-secretases within the transmembrane region, releasing their intracellular domains (ICDs) into the cytosol. Therefore, we identify TrkB-FL and TrkB-T1 as new substrates of regulated intramembrane proteolysis (RIP), a mechanism that highly contributes to TrkB-T1 regulation in ischaemia but is minor for TrkB-FL which is mainly processed by calpain. However, since the secreted TrkB ectodomain acts as a BDNF-scavenger and significantly alters BDNF/TrkB-signalling, the mechanism of RIP could contribute to neuronal death in excitotoxicity. These results are highly relevant since they reveal new targets for the rational design of therapies to treat stroke and other pathologies with an excitotoxic component., This work was supported by the Ministerio de Economía y Competitividad (BFU2010-18380/BFI and BFU2013-43808-R) and Fundación Mutua Madrileña (reference No 201322001). GST was funded by contracts from projects BFU2010-18380/BFI, Fundación Mutua Madrileña and BFU2013-43808-R. SA-D is a recipient of a FPI pre-doctoral fellowship associated with BFU2010-18380/BFI. GME-O is funded by a contract associated with project BFU2013-43808-R., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Development of a neuroprotective peptide that preserves survival pathways by preventing Kidins220/ARMS calpain processing induced by excitotoxicity

  • Gamir-Morralla, Andrea
  • López-Menéndez, Celia
  • Ayuso Dolado, Sara
  • Tejeda, Gonzalo S.
  • Montaner, J.
  • Iglesias, Teresa
  • Díaz-Guerra, Margarita
Kinase D-interacting substrate of 220kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), has a central role in the coordination of receptor crosstalk and the integration of signaling pathways essential for neuronal differentiation, survival and function. This protein is a shared downstream effector for neurotrophin- and ephrin-receptors signaling that also interacts with the N-methyl-d-aspartate type of glutamate receptors (NMDARs). Failures in neurotrophic support and glutamate signaling are involved in pathologies related to excitotoxicity and/or neurodegeneration, where different components of these dynamic protein complexes result altered by a combination of mechanisms. In the case of Kidins220/ARMS, overactivation of NMDARs in excitotoxicity and cerebral ischemia triggers its downregulation, which contributes to neuronal death. This key role in neuronal life/death decisions encouraged us to investigate Kidins220/ARMS as a novel therapeutic target for neuroprotection. As the main mechanism of Kidins220/ARMS downregulation in excitotoxicity is proteolysis by calpain, we decided to develop cell-penetrating peptides (CPPs) that could result in neuroprotection by interference of this processing. To this aim, we first analyzed in detail Kidins220/ARMS cleavage produced in vitro and in vivo, identifying a major calpain processing site in its C-terminal region (between amino acids 1669 and 1670) within a sequence motif highly conserved in vertebrates. Then, we designed a 25-amino acids CPP (Tat-K) containing a short Kidins220/ARMS sequence enclosing the identified calpain site (amino acids 1668-1681) fused to the HIV-1 Tat protein basic domain, able to confer membrane permeability to attached cargoes. Transduction of cortical neurons with Tat-K reduced Kidins220/ARMS calpain processing in a dose- and time-dependent manner upon excitotoxic damage and allowed preservation of the activity of pERK1/2 and pCREB, signaling molecules central to neuronal survival and functioning. Importantly, these effects were associated to a significant increase in neuronal viability. This Kidins220/ARMS-derived peptide merits further research to develop novel neuroprotective therapies for excitotoxicity-associated pathologies., This work was supported by the Ministerio de Economía y Competitividad (SAF2011-26233 and SAF2014-52737- P to TI, BFU2010-18380/BFI and BFU2013-43808- R to MD-G.); Comunidad de Madrid (P2010/BMD-2331-Neurodegmodels to TI) and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, Instituto de Salud Carlos III, to TI). CL-M was a recipient of a contract from SAF2011-26233; AG-M has been funded by contracts from P2010/BMD-2331, SAF2011-26233 and CIBERNED; SAD is a recipient of a FPI pre-doctoral fellowship associated to BFU2010-18380/BFI and GST has been funded by contracts from Consejo Superior de Investigaciones Cientıficas associated to projects BFU2010-18380/BFI and BFU2013-43808- R., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Desarrollo de péptidos neuroprotectores frente a la isquemia cerebral basados en el receptor de glutamato de tipo NMDA y su proteína interaccionante PSD-95

  • Ayuso Dolado, Sara
El Trabajo presentado en esta memoria ha sido realizado en el Departamento de Fisiopatología Endocrina y del Sistema Nervioso del Instituto de Investigaciones Biomédicas “Alberto Sols” de Madrid (CSIC-UAM), por Sara Ayuso Dolado Licenciada en Biología y Bioquímica, para optar al grado de Doctora., [ES] La activación fisiológica del receptor de glutamato de tipo N-metil-D-aspartato (NMDAR) promueve la supervivencia neuronal y es crítica en procesos de plasticidad sináptica, memoria y aprendizaje. Por el contrario, su activación patológica conduce a una forma de muerte neuronal denominada excitotoxicidad, responsable principal de la degeneración neuronal secundaria propia de la isquemia cerebral y también asociada con hipoglucemia, enfermedades neurodegenerativas y otras patologías neurológicas. En excitotoxicidad, la pérdida de homeostasis del Ca2+ provoca la activación de la proteasa calpaína que, entre otros sustratos, procesa eficientemente las subunidades GluN2 del NMDAR y su proteína interaccionante PSD-95 (postsynaptic density-95). Este procesamiento genera subunidades GluN2A truncadas, deficientes en la señalización prosupervivencia, y fragmentos estables de PSD-95 que desacoplan la red de interacciones proteicas mediada por esta proteína de andamiaje en la PSD. En este Tesis, hemos caracterizado el procesamiento de PSD-95 en un modelo en rata de daño neuronal inducido por hipoglucemia, donde la excitotoxicidad y la activación de calpaína en corteza parietal y estriado originan fragmentos de PSD-95 en proporción a la severidad del daño. El procesamiento de PSD-95 en regiones interdominio discretas es muy similar al identificado en modelos celulares de excitotoxicidad y de isquemia permanente en ratón, donde la fragmentación es un proceso muy temprano. El procesamiento de GluN2A en el tejido infartado es igualmente temprano aunque mucho más complejo, dando lugar a un gran fragmento N-terminal muy estable y múltiples fragmentos intracelulares de baja estabilidad. Para interferir el procesamiento de GluN2A y PSD-95 en excitotoxicidad, hemos desarrollado diferentes péptidos conteniendo pequeñas secuencias de estas proteínas a continuación de una secuencia de la proteína Tat del VIH que confiere permeabilidad a la membrana plasmática y a la barrera hematoencefálica. Entre los péptidos diseñados para PSD-95, TP95414 (aa. 414-427) previene eficientemente su degradación y mejora la supervivencia neuronal en excitotoxicidad in vitro, si bien no hemos podido demostrar todavía un efecto neuroprotector en isquemia. Por otra parte, TG2A1179 (aa. 1179-1192) interfiere el procesamiento de GluN2A inducido in vitro y preserva la activación de los factores de transcripción CREB y MEF2, que mantienen su actividad promotora sobre la transcripción de genes prosupervivencia como el receptor de neurotrofinas TrkB, su ligando BDNF o las propias subunidades GluN2A y GluN1 del NMDAR. Los resultados muestran también que la susceptibilidad de GluN2A al procesamiento depende del estado de fosforilación de sus tirosinas y sugieren fuertemente que el efecto neuroprotector establecido para TG2A1179 es debido al mantenimiento específicamente de la fosforilación de los residuos Y1184 y/o Y1187. Estos aminoácidos tendrían, por tanto, un papel regulador clave sobre la estabilidad de GluN2A y su fosforilación disminuiría la susceptibilidad de la subunidad al procesamiento. Finalmente, una forma modificada de este péptido, MTG2A1179, que previsiblemente aumenta su estabilidad en plasma, tiene un efecto neuroprotector in vivo ya que reduce de manera estadísticamente significativa el volumen de tejido cerebral infartado y provoca una recuperación funcional en isquemia cerebral permanente. Estos resultados señalan la importancia de preservar la señalización fisiológica de los NMDARs formados por subunidades GluN2A en situaciones de daño cerebral y el enorme interés de esta proteína como diana terapéutica en neuroprotección., [EN] Activation of the N-methyl-D-aspartate type of glutamate receptor (NMDAR) in physiological conditions promotes neuronal survival and is critical in processes such as synaptic plasticity, memory and learning. However, its pathological activation leads to a form of neuronal death known as excitotoxicity which is largely responsible for secondary neurodegeneration in stroke and is also associated with hypoglycemia, neurodegenerative diseases and other neurological pathologies. The loss of Ca2+ homeostasis during excitotoxicity causes calpain activation which, among other substrates, efficiently cleaves GluN2 subunits of NMDARs and their interacting protein PSD-95 (postsynaptic density-95). Such calpain processing generates truncated GluN2A subunits unable to maintain prosurvival signaling and stable PSD-95 fragments that provoke uncoupling of multiple proteins interacting with this scaffolding protein in the PSD. In this work, we have characterized PSD-95 proteolytic processing in vivo using a rat model of hypoglycemia where excitotoxicity and calpain activation in parietal cortex and striatum generate stable PSD-95 fragments in correlation to the severity of neuronal damage. PSD-95 processing within discrete interdomain regions is very similar to that identified in a cellular model of excitotoxicity or a mice model of permanent ischemia where PSD-95 cleavage is an early process along brain damage. GluN2A processing in the infarcted tissue is similarly an early process but far more complex, resulting in a very large stable N-terminal fragment and multiple intracellular fragments of reduced stability. To interfere GluN2A and PSD-95 processing induced by excitotoxicity, we have developed different peptides that contain short sequences of these proteins located after a HIV Tat sequence which confers the capability to cross the plasma membrane and the blood-brain barrier. Among the peptides designed for PSD-95, TP95414 (aa. 414-427) can efficiently prevent this protein proteolytic degradation, a result correlating with enhancement of neuronal survival under in vitro excitotoxicity. However, we could not demonstrate so far a neuroprotective effect of TP95414 in the ischemia model. On the other hand, peptide TG2A1179 (aa. 1179-1192) interferes in vitro induced GluN2A processing and preserves activation of the transcription factors CREB and MEF2, thus maintaining their promoter activity over the transcription of prosurvival genes, such as the neurotrophin receptor TrkB, its ligand BDNF, or the NMDAR subunits themselves, GluN2A and GluN1. In addition, our results demonstrate that GluN2A susceptibility to calpain processing depends on the phosphorylation status of the subunit tyrosines while strongly suggest that the neuroprotective effect of TG2A1179 could be due to the the maintenance of the specific phosphorylation of GluN2A tyrosine residues Y1184 and/or Y1187. Therefore, these aminoacids could have a key regulatory role on GluN2A stability and their phosphorylation would decrease the subunit susceptibility to calpain processing. Finally, a modified form of this peptide, MTG2A1179, which presumably increases peptide stability in plasma, has also a neuroprotective effect in vivo since it significantly reduces the volume of infarcted brain tissue and causes functional recovery in a model of permanent cerebral ischemia. These results unveil the relevance of preserving physiological signaling of NMDARs containing GluN2A subunits after brain damage and the importance of this protein as a therapeutic target in neuroprotection., La realización de esta Tesis Doctoral ha sido posible gracias a la concesión de una beca para la Formación de Personal Investigador (FPI, 2011-2015) así como a un contrato de titulado superior en actividades técnicas y profesionales financiado por el proyecto BFU2013-43808-R del Ministerio de Economía y Competitividad (2015-2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prevention of excitotoxicity-induced processing of BDNF receptor TrkB-FL leads to stroke neuroprotection

  • Tejeda, Gonzalo S.
  • Esteban‐Ortega, Gema M.
  • San Antonio, Esther
  • Gómez Vidaurre, Óscar
  • Díaz-Guerra, Margarita
© 2019 The Authors., Neuroprotective strategies aimed to pharmacologically treat stroke, a prominent cause of death, disability, and dementia, have remained elusive. A promising approach is restriction of excitotoxic neuronal death in the infarct penumbra through enhancement of survival pathways initiated by brain‐derived neurotrophic factor (BDNF). However, boosting of neurotrophic signaling after ischemia is challenged by downregulation of BDNF high‐affinity receptor, full‐length tropomyosin‐related kinase B (TrkB‐FL), due to calpain‐degradation, and, secondarily, regulated intramembrane proteolysis. Here, we have designed a blood–brain barrier (BBB) permeable peptide containing TrkB‐FL sequences (TFL457) which prevents receptor disappearance from the neuronal surface, early induced after excitotoxicity. In this way, TFL457 interferes TrkB‐FL cleavage by both proteolytic systems and increases neuronal viability via a PLCγ‐dependent mechanism. By preserving downstream CREB and MEF2 promoter activities, TFL457 initiates a feedback mechanism favoring increased levels in excitotoxic neurons of critical prosurvival mRNAs and proteins. This neuroprotective peptide could be highly relevant for stroke therapy since, in a mouse ischemia model, it counteracts TrkB‐FL downregulation in the infarcted brain, efficiently decreases infarct size, and improves neurological outcome., We acknowledge funding from Ministerio de Economía y Competitividad (BFU2013-43808-R and BFU2016-75973-R). The cost of publication has been paid in part by FEDER funds. Contracts were funded associated with projects BFU2013-43808-R (G.S.T and G.M.E-O) and BFU2016-75973-R (G.M.E-O and E.SA).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel cell-penetrating peptide targeting calpain-cleavage of PSD-95 induced by excitotoxicity improves neurological outcome after stroke

  • Ayuso Dolado, Sara
  • Esteban-Ortega, Gema M.
  • Gómez Vidaurre, Óscar
  • Díaz-Guerra, Margarita
© The author(s)., Postsynaptic density protein-95 (PSD-95) is a multidomain protein critical to the assembly of signaling complexes at excitatory synapses, required for neuronal survival and function. However, calpain-processing challenges PSD-95 function after overactivation of excitatory glutamate receptors (excitotoxicity) in stroke, a leading cause of death, disability and dementia in need of efficient pharmacological treatments. A promising strategy is neuroprotection of the infarct penumbra, a potentially recoverable area, by promotion of survival signaling. Interference of PSD-95 processing induced by excitotoxicity might thus be a therapeutic target for stroke and other excitotoxicity-associated pathologies. [Methods]: The nature and stability of PSD-95 calpain-fragments was analyzed using in vitro assays or excitotoxic conditions induced in rat primary neuronal cultures or a mouse model of stroke. We then sequenced PSD-95 cleavage-sites and rationally designed three cell-penetrating peptides (CPPs) containing these sequences. The peptides effects on PSD-95 stability and neuronal viability were investigated in the cultured neurons, subjected to acute or chronic excitotoxicity. We also analyzed the effect of one of these peptides in the mouse model of stroke by measuring infarct size and evaluating motor coordination and balance. [Results]: Calpain cleaves three interdomain linker regions in PSD-95 and produces stable fragments corresponding to previously described PSD-95 supramodules (PDZ1-2 and P-S-G) as well as a truncated form SH3-GK. Peptide TP95414, containing the cleavage site in the PDZ3-SH3 linker, is able to interfere PSD-95 downregulation and reduces neuronal death by excitotoxicity. Additionally, TP95414 is delivered to mice cortex and, in a severe model of permanent ischemia, significantly improves the neurological outcome after brain damage. [Conclusions]: Interference of excitotoxicity-induced PSD-95-processing with specific CPPs constitutes a novel and promising therapeutic approach for stroke treatment., We acknowledge funding from Ministerio de Economía y Competitividad (BFU2013-43808-R and BFU2016-75973-R) and from Agencia Estatal de Investigación (PID2019-105784RB-100/AEI/10.13039/501100011033). The cost of publication has been paid in part by FEDER funds. Contracts were funded associated to projects BFU2013-43808-R (G.M. E-O and S.A-D) and BFU2016-75973-R (G.M.E-O). We are grateful to Dr. Sobrado (HU La Princesa) and Drs. Avendaño and Negredo (Departamento de Anatomía, Histología y Neurociencia, UAM, Spain) for technical advice with the ischemia model, and Dr. Scheiffele for sharing plasmid pNice-PSD-95-YFP